SAN DIEGO, Calif-NewBiotics, Inc announced January 8, that H. Michael Shepard, will be the company's president.
Shepard will be responsible for overseeing all aspects of the company's research and development strategies, scientific and corporate collaborations, and related activities.
NewBiotics, a developer of drugs targeted against cancer and infectious disease, is privately held. The company's drugs use a "Trojan horse solution" to fight various diseases.
Shepard, who previously worked for Canji, and Genentech, helped develop the p53gene product for cancer therapy.
Gag Order Puts Public Health at Risk, APIC Urges Immediate Action
February 4th 2025APIC warns that the HHS gag order on CDC communications endangers public health, delaying critical infection updates and weakening outbreak response amid rising tuberculosis, avian flu, Ebola, and measles threats.
Breaking Barriers: The Future of HIV Prevention and the Fight for Widespread PrEP Access
January 31st 2025Despite medical advances, HIV prevention faces roadblocks—low PrEP adoption, stigma, and accessibility issues threaten progress. Experts push for innovative, long-acting solutions to end the epidemic.
The Hidden Dangers of Hospital Ventilation: Are We Spreading Viruses Further?
January 31st 2025New research reveals hospital ventilation and air purifiers may unintentionally spread viral particles, increasing infection risks. Infection preventionists must rethink airflow strategies to protect patients and staff.